Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ: IOVA · IEX Real-Time Price · USD
12.36
-0.83 (-6.29%)
At close: Apr 12, 2024, 4:00 PM
12.30
-0.06 (-0.49%)
After-hours: Apr 12, 2024, 7:58 PM EDT
-6.29%
Market Cap 3.45B
Revenue (ttm) 1.19M
Net Income (ttm) -444.04M
Shares Out 279.31M
EPS (ttm) -1.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,426,929
Open 13.01
Previous Close 13.19
Day's Range 12.15 - 13.13
52-Week Range 3.21 - 18.33
Beta 0.59
Analysts Strong Buy
Price Target 25.64 (+107.44%)
Earnings Date May 7, 2024

About IOVA

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combinat... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 557
Stock Exchange NASDAQ
Ticker Symbol IOVA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for IOVA stock is "Strong Buy." The 12-month stock price forecast is $25.64, which is an increase of 107.44% from the latest price.

Price Target
$25.64
(107.44% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deliver...

21 days ago - GlobeNewsWire

Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer

SAN CARLOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclon...

5 weeks ago - GlobeNewsWire

Iovance Biotherapeutics to Present at Upcoming Conferences

SAN CARLOS, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in...

6 weeks ago - GlobeNewsWire

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Amtagvi™ (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the First and Only One-Time, Individualized T cell Therapy for a Solid Tumor Cancer

6 weeks ago - GlobeNewsWire

Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024

SAN CARLOS, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...

7 weeks ago - GlobeNewsWire

Iovance Biotherapeutics Stock Rockets 41% Higher. Here's Why.

Shares of the biotechnology company are on pace for their best day since June 2016.

7 weeks ago - Barrons

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma

AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer. PHILADELPHIA , Feb. 20, 2024 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ...

7 weeks ago - PRNewsWire

Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock

SAN CARLOS, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering n...

7 weeks ago - GlobeNewsWire

Iovance (IOVA) stock price could rocket higher ahead of earnings

Iovance Biotherapeutics (NASDAQ: IOVA) stock price has rebounded this year and is hovering at its highest point since October 2022. It has risen by over 120% as investors focus on the upcoming earning...

7 weeks ago - Invezz

FDA Approves First Cellular Treatment For Advanced Melanoma

The Food and Drug Administration approved a groundbreaking cellular treatment Friday for two types of advanced melanoma aimed at combating tumor growth in adult patients with the skin cancer who have ...

2 months ago - Forbes

US FDA grants accelerated approval for Iovance's skin cancer cell therapy

Iovance Biotherapeutics said on Friday the U.S. health regulator had granted accelerated approval for its cell therapy for adult patients with advanced melanoma, the first such treatment to be approve...

2 months ago - Reuters

Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024

SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...

2 months ago - GlobeNewsWire

Iovance's AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma

AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy

2 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

NEW YORK , Jan. 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). Such investors are a...

2 months ago - PRNewsWire

3 Charts For Investors to Watch Thursday: GC Education, Iovance, Ethereum

Here's our daily look at three charts connected to recent news-driven price moves, with key technical levels to monitor.

Other symbols: LOPE
3 months ago - Investopedia

Iovance stock drops 23% in premarket trades after it halts cancer drug trial

Iovance Biotherapeutics Inc.'s stock IOVA, +6.59% fell 22.6% in premarket trading on Wednesday after the cancer therapy company said the U.S. Food and Drug Administration placed a clinical hold on its...

3 months ago - Market Watch

Iovance's IOVA stock price suffers a harsh reversal: buy the dip?

Iovance Biotherapeutics (NASDAQ: IOVA) stock price suffered a harsh reversal on Wednesday after the company suffered a major setback. The stock, which has been in a strong uptrend, crashed by more tha...

3 months ago - Invezz

Iovance Stock Plunges as FDA Puts Hold on Lung Cancer Study After Patient Death

The FDA places a clinical hold on Iovance's trial of a lung cancer therapy after the company reports a death potentially related to the treatment.

3 months ago - Barrons

US FDA places clinical hold on Iovance's lung cancer treatment trial

Iovance Biotherapeutics said on Wednesday that the U.S. Food and Drug Administration has placed a clinical hold on its trial on a therapy for a type of lung cancer.

3 months ago - Reuters

US FDA puts clinical hold on Iovance's cancer therapy trial

The U.S. health regulator has placed a clinical hold on Iovance Biotherapeutics' trial of its experimental cell therapy in lung cancer patients after a patient death, the company said on Wednesday, se...

3 months ago - Reuters

Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer

SAN CARLOS, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infi...

3 months ago - GlobeNewsWire

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates

FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act Action (PDUFA) Date of February 24, 2023

5 months ago - GlobeNewsWire

Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023

SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...

5 months ago - GlobeNewsWire

Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer's (SITC) 38th Annual Meeting

SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...

5 months ago - GlobeNewsWire

Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress

SAN CARLOS, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...

6 months ago - GlobeNewsWire